Mark J. Foley, CEO at Revance Therapeutics, Inc. (RVNC), sold 52,558 shares at $22.57 ($1.2M) on 2023-08-03, disclosed to the SEC on 2023-08-04.
Scheduled sale ($1.2M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.57 | 26,279 | $593K | 50.0% |
| 2 | $22.57 | 26,279 | $593K | 50.0% |
| Total | $22.57 avg | 52,558 | $1.2M | 100% |
| Filing → |
| GKOS | SELL | 2024-02-26 | $847K | — | Filing → |
| RVNC | SELL | 2023-07-05 | $1.3M | — | Filing → |
| RVNC | SELL | 2023-06-13 | $1.9M | — | Filing → |